From GlobeNewswire: 2025-03-19 16:05:00

LENZ Therapeutics, Inc. reports a successful year with progress towards potential approval and launch of LNZ100 for presbyopia treatment. NDA for LNZ100 accepted by FDA with a PDUFA target action date of August 8, 2025. Cash position as of December 31, 2024, stands at $209.1 million, supporting operations post-launch. Company to host conference call today at 4:30 p.m. EST.

Pre-commercial planning for LNZ100 in the U.S. advances ahead of potential August 2025 approval. Positive topline data from Phase 3 study in China for LNZ100 announced. Commercial Day scheduled for April 15, 2025, to discuss commercialization strategy and progress towards approval. Financial results show cash position, R&D, and SG&A expenses for three months and year ended December 31, 2024.

Upon FDA approval, commercial launch activities for LNZ100 expected to begin with product availability in the fourth quarter of 2025. LENZ Therapeutics focuses on developing the first aceclidine-based eye drop for presbyopia. Net loss for the three months ended December 31, 2024, was $12.7 million, compared to $23.7 million in 2023. Conference call and webcast scheduled for today at 4:30 p.m. EST.

Forward-looking statements in press release include NDA review by FDA, potential approval and commercialization of LNZ100, and plans for commercialization. Contact for more information provided. Selected consolidated balance sheet highlights and statement of operations and comprehensive loss for three months and year ended December 31, 2024, also detailed.LENZ Therapeutics aims to enhance vision for presbyopia patients with LNZ100, a preservative-free eye drop containing aceclidine.



Read more at GlobeNewswire:: LENZ Therapeutics Reports Fourth Quarter and Full Year 2024